Cristian Moreno – Managing Director – Torque Metals (ASX:TOR) is an exploration company with a proven discovery methodology, combining drilling results with machine learning algorithms and geological interpretation.
Copyright 2024 – Finance News Network
28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
10 Oct 2023 - Alex Hanly - CEO - Lithium Universe (ASX:LU7) objective is to construct a Lithium Project in Québec with utmost speed, and to assist Canada facilitate the transition towards cleaner energy.
03 Nov 2022 - Antisense Therapeutics Limited (ASX:ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense's progress, attracting new talent to the company, and what drew Dr Filippis to the role.
17 Dec 2019 - Aus Tin Mining Limited (ASX:ANW) CEO, Peter Williams discusses the funding package and resumption plan for the Granville Tin Project and plans for Granville to be a foundation asset in a proposed IPO.
03 February 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar talks about the company's collaboration agreement with the Walter Reed Army Institute of Research and UNSW into the study of a first-ever pharmaceutical treatment for traumatic brain injury, a top health priority for the military.
02 Jun 2021 - Next Science Limited (ASX:NXS) Managing Director Judith Mitchell talks about the company's antimicrobial wound gel BlastX, and its health benefits for the treatment of chronic wounds and ulcers.
06 Sep 2023 - Sequoia Financial Group Limited (ASX:SEQ) CEO and Managing Director Garry Crole discusses financial highlights, drivers of growth and revenue going forward, M&A, and cash deployment.
27 Nov 2020 - Novatti Group Limited (ASX:NOV) Managing Director & CEO Peter Cook talks about the company's recently announced partnerships with UnionPay, Google Pay and Samsung Pay.
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.